Few areas of medicine have attracted more controversy than prostate cancer screening (PSA) and early intervention in prostate cancer. Much of this followed two landmark trials (PLCO and ERSPC) that did not show a significant mortality benefit for PSA screening.
This content is restricted to Medical Forum readers; this is a new feature. If you haven’t registered with our site in the last few weeks, please create a new account below. If you have subscribed, please log in.